Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (NYSE: EBS) is a life sciences company developing and supplying products and services for public health threats, including biological and chemical threats, infectious diseases and opioid overdose emergencies. Its portfolio includes medical countermeasure products such as ACAM2000® smallpox… From the company’s description.
Over the twelve months to Sep 30, 2026, Emergent BioSolutions Inc. reported revenue of $649.10M, down 17.7% from a year earlier, and a net loss of $260.70M. Its operating margin was −27.7%, and operations generated $200.10M in cash. In fiscal 2025, it reported revenue of $742.90M, down 28.8% from fiscal 2024, and net income of $52.60M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Emergent BioSolutions Inc. does
In the company’s own words
Emergent BioSolutions Inc. (NYSE: EBS) is a life sciences company developing and supplying products and services for public health threats, including biological and chemical threats, infectious diseases and opioid overdose emergencies. Its portfolio includes medical countermeasure products such as ACAM2000® smallpox and mpox vaccine, BioThrax® and CYFENDUS® anthrax vaccines, BAT® botulism antitoxin, Ebanga™ for Ebola and TEMBEXA® for smallpox, as well as NARCAN® and KLOXXADO® naloxone nasal sprays. Government customers, particularly the U.S. government, procure its medical countermeasures; its naloxone products are sold to governments, first responders, organizations, pharmacies and consumers in the United States and Canada. The business is organized around Commercial Products, MCM Products and Services, although Services is included in “All other revenues” rather than reported as a separate reportable segment. Services include drug substance and drug product manufacturing, development, analytical and packaging work for pharmaceutical and biotechnology companies, governments and NGOs. In 2025, revenue totaled $[not stated in provided text]. Its website is www.emergentbiosolutions.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- GAITHERSBURG, MD
- Fiscal year end
- December
- CIK
- 1367644
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Emergent BioSolutions Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Emergent BioSolutions Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Emergent BioSolutions Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Emergent BioSolutions Inc.’s debt, $120.08M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.88%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Emergent BioSolutions Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Emergent BioSolutions Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Emergent BioSolutions Inc.'s last four quarterly filings that the numbers alone won't show?”